We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) closed the most recent trading day at $1.17, making no change from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.67%. Meanwhile, the Dow experienced a rise of 1.07%, and the technology-dominated Nasdaq saw an increase of 2.5%.
The the stock of maker of genetic analysis technology has fallen by 10.69% in the past month, lagging the Medical sector's loss of 9.34% and the S&P 500's loss of 6.57%.
Market participants will be closely following the financial results of Pacific Biosciences of California in its upcoming release. The company is expected to report EPS of -$0.19, up 26.92% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $35 million, down 9.82% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.71 per share and a revenue of $158.74 million, indicating changes of +14.46% and +3.07%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.95% lower. At present, Pacific Biosciences of California boasts a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 86, finds itself in the top 35% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know
Pacific Biosciences of California (PACB - Free Report) closed the most recent trading day at $1.17, making no change from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.67%. Meanwhile, the Dow experienced a rise of 1.07%, and the technology-dominated Nasdaq saw an increase of 2.5%.
The the stock of maker of genetic analysis technology has fallen by 10.69% in the past month, lagging the Medical sector's loss of 9.34% and the S&P 500's loss of 6.57%.
Market participants will be closely following the financial results of Pacific Biosciences of California in its upcoming release. The company is expected to report EPS of -$0.19, up 26.92% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $35 million, down 9.82% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.71 per share and a revenue of $158.74 million, indicating changes of +14.46% and +3.07%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.95% lower. At present, Pacific Biosciences of California boasts a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 86, finds itself in the top 35% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.